Table 3:
Characteristics of patients categorized as progressors or non-progressors according to IgAN237s and eGFR values at baseline between 15 and 90 mL/min/1.73 m2.
| Non-progressors | Progressors | T-test | Mann–Whitney test | |||||
|---|---|---|---|---|---|---|---|---|
| Variables | N | Mean | SD | N | Mean | SD | P-value | P-value |
| (A) Progressors and non-progressors at baseline | ||||||||
| IgAN237-1 | 52 | –0.418 | 0.586 | 22 | 0.863 | 0.455 | <.001 | <.001 |
| Male (%) | 52 | 56 | 22 | 77 | .067* | |||
| Age at diagnosis (1st biopsy) (years) | 52 | 48.1 | 16.0 | 22 | 46.1 | 14.7 | .601 | .696 |
| Age at baseline (IgAN237-1) (years) | 52 | 59.7 | 14.0 | 22 | 52.7 | 13.4 | .052 | .036 |
| Baseline eGFR (mL/min/1.73 m2) | 52 | 49.9 | 17.9 | 22 | 44.7 | 22.7 | .292 | .208 |
| Baseline UACR (g/mol) | 48 | 43.0 | 97.8 | 20 | 86.6 | 75.3 | .08 | <.001 |
| Hematuria [N (%)] | 45 | 47% | 18 | 44% | .549* | |||
| Number of antihypertensive drugs at baseline (N) | 52 | 2.1 | 1.4 | 22 | 2.3 | 1.3 | .621 | .534 |
| Biopsy: glomerular sclerosis (% of glomeruli) | 38 | 19.3 | 14.4 | 21 | 27.3 | 17.4 | .065 | .069 |
| Biopsy: interstitial fibrosis (% of kidney surface) | 43 | 25.9 | 18.6 | 22 | 30 | 13.2 | .357 | .439 |
| Biopsy: crescents (% of biopsies with crescents) | 41 | 29% | 22 | 18% | .258* | |||
| eGFRTotal-slope (mL/min/1.73 m2/year) | 49 | 0.57 | 3.54 | 21 | –1.92 | 2.82 | .006 | .01 |
| eGFRChron-slope (mL/min/1.73 m2/year) | 49 | –0.15 | 3.38 | 21 | –2.73 | 2.80 | .003 | .003 |
| eGFRProsp-slope (mL/min/1.73 m2/year) | 49 | –0.73 | 6.60 | 21 | –3.12 | 7.98 | .197 | .04 |
| eGFR180days-slope (mL/min/1.73 m2/year) | 49 | –0.91 | 5.07 | 21 | –8.47 | 7.59 | <.001 | <.001 |
| UACRTotal-slope (g/mol/year) | 48 | –48.9 | 148 | 21 | –0.03 | 7.66 | .136 | .064 |
| UACRChron-slope (g/mol/year) | 48 | –8.56 | 35.3 | 21 | 2.1 | 11.7 | .179 | .091 |
| UACRProsp-slope (g/mol/year) | 46 | –14.7 | 47.5 | 18 | –3.0 | 49.2 | .383 | .66 |
| UACR180days-slope (g/mol/year) | 46 | –31.5 | 160 | 18 | 25.1 | 65.0 | .153 | .019 |
| (B) Progressors and non-progressors at follow-up | ||||||||
| IgAN237-1 (value) | 41 | –0.406 | 0.566 | 16 | 0.819 | 0.319 | <.001 | <.001 |
| Sex (male, %) | 41 | 56% | 16 | 69% | .285* | |||
| Age at diagnosis (1st biopsy) (years) | 41 | 51.3 | 15.4 | 16 | 40.9 | 13.3 | .022 | .015 |
| Age at follow-up (IgAN237-1) (years) | 41 | 62.9 | 10.8 | 16 | 51.5 | 15.1 | .002 | .011 |
| Follow-up eGFR (mL/min/1.73 m2) | 41 | 49.3 | 20.6 | 16 | 44.2 | 20.0 | .402 | .36 |
| Follow-up UACR (g/mol) | 35 | 25.2 | 29.8 | 13 | 71.0 | 59.2 | .018 | .003 |
| Hematuria [N (%)] | 37 | 41% | 13 | 46% | .486* | |||
| Number of antihypertensive drugs at baseline (N) | 41 | 2.05 | 1.26 | 16 | 1.75 | 1.18 | .418 | .337 |
| Biopsy: glomerular sclerosis (% of glomeruli) | 33 | 18.9 | 15.3 | 13 | 28.2 | 17.3 | .08 | .067 |
| Biopsy: interstitial fibrosis (% of kidney surface) | 36 | 24.5 | 18.1 | 13 | 28.2 | 18.3 | .531 | .497 |
| Biopsy: crescents (% of biopsies with crescents) | 34 | 29% | 13 | 23% | .482* | |||
| eGFRTotal-slope (mL/min/1.73 m2/year) | 40 | 0.65 | 4.01 | 15 | –0.70 | 2.77 | .238 | .303 |
| eGFRChron-slope (mL/min/1.73 m2/year) | 40 | –0.18 | 3.74 | 15 | –2.29 | 2.18 | .045 | .014 |
| eGFRProsp-slope (mL/min/1.73 m2/year) | 38 | 1.60 | 15.6 | 15 | 5.11 | 11.3 | .431 | .813 |
| eGFR180days-slope (mL/min/1.73 m2/year) | 38 | 1.15 | 8.61 | 15 | –3.20 | 7.74 | .095 | .005 |
| UACRTotal-slope (g/mol/year) | 40 | –42.4 | 141 | 16 | –8.42 | 37.5 | .349 | .095 |
| UACRChron-slope (g/mol/year) | 40 | –5.72 | 16.4 | 16 | 3.14 | 12.9 | .058 | .157 |
| UACRProsp-slope (g/mol/year) | 33 | 9.74 | 61.4 | 13 | 11.4 | 57.2 | .935 | .76 |
| UACR180days-slope (g/mol/year) | 33 | –12.8 | 48.9 | 13 | 21.1 | 51.1 | .043 | .095 |
N = number; SD = standard deviation; * = Fisher's exact test.